Parasitic Infections and Ulcerative Colitis: Combining Anti-parasitic and Immunomodulatory Treatments May Achieve Remission
NCT ID: NCT06583863
Last Updated: 2024-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2023-09-12
2024-06-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
NCT03441893
Chronic Diarrhea Owing to Underlying Microscopic Colitis
NCT06530836
Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis
NCT04750135
Fecal Microbiota Transplantation for Ulcerative Colitis
NCT03804931
Metformin as Added on Therapy in Patients With Ulcerative Colitis
NCT05574387
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Echinacea Extract
175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
Group I
MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]
500 mg of metronidazole was provided as an oral tablets twice daily
Group II
Echinacea Extract
175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]
500 mg of metronidazole was provided as an oral tablets twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Echinacea Extract
175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]
500 mg of metronidazole was provided as an oral tablets twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients had parasitic infection by G. lambellia,
* Patients free of parasitic infection,
Exclusion Criteria
* Patients had multiple parasitic infections,
* Patients had infection by parasites other than G. lambellia,
* Patients who were maintained on immunosuppressant therapy,
* Patients who were in remission and patients refused to sign the written consent to participate in the study.
20 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Heba M. Aboelela
Lecturer of Medical Parasitology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha faculty of Medicine
Banhā, El Qalyoubia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC 16-7-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.